Search

everythinglearnresearchcommunity

for

Search:↓

Quercetin and kaempferol may be effective and safe natural treatments for hair loss.

Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.

Apremilast did not work for treating severe alopecia areata.

Majocchi's granuloma can occur in kidney transplant patients on tacrolimus and can be treated with antifungal medication.

Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.

Quercetin and kaempferol may be effective and safe natural treatments for hair loss.

T cell subsets are crucial in kidney cancer, and a new model predicts patient outcomes using key genes.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.

Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.

Combination therapy, including JAK inhibitors, effectively regrows hair and reduces severity in Black children with stubborn Alopecia Areata.

The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.

Combining delgocitinib ointment with excimer laser can effectively treat severe alopecia areata.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

Ritlecitinib is cost-effective for severe alopecia areata in Japan.

CDK4/6 inhibitors can protect hair cells from chemotherapy damage.

Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

Targeting JAK-STAT1 can reduce inflammation and promote hair growth in conditions linked to EGFR deficiency.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.

Sorafenib often causes skin side effects, indicating effective cancer treatment.